Long-Term Follow-Up of Children With Congenital Hyperinsulinism on Octreotide Therapy


Creative Commons License

Demirbilek H., Shah P., Arya V. B., Hinchey L., Flanagan S. E., Ellard S., ...Daha Fazla

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, cilt.99, sa.10, ss.3660-3667, 2014 (SCI-Expanded, Scopus)

Özet

Context: Octreotide, a somatostatin analog, is commonly used in diazoxide unresponsive congenital hyperinsulinism (CHI) patients as a second-line therapy.